Table 2.
Treatment characteristics and efficacy
| Author | Year | Microsphere | Dosimetric calculation | Follow-up (months) | Median OS (months) | 1-year survival | Evaluation criteria | Recist | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | SD | PD | ||||||||
| Saxena et al26 | 2010 | Resin | BSA | 8.1 | 9.3 | 40.0% | RECIST | 0 | 6 | 11 | 5 |
| Mosconi et al25 | 2016 | Resin | BSA | 16.0 | 17.9 | 67.9% | RECIST | 0 | 4 | 11 | 5 |
| mRECIST | 1 | 13 | 3 | 3 | |||||||
| EASL | 1 | 11 | 5 | 3 | |||||||
| Rafi et al24 | 2013 | Resin | BSA | 15.0 | 11.5 | 56.0% | RECIST | 0 | 2 | 13 | 4 |
| Mouli et al23 | 2013 | Glass | N/A | 29.0 | N/A | N/A | WHO | 0 | 11 | 33 | 1 |
| EASL | 4 | 28 | - | 0 | |||||||
| Hoffmann et al22 | 2012 | Resin | BSA | 10 | 22.0 | N/A | RECIST | 0 | 12 | 17 | 5 |
| Jia et al21 | 2017 | Resin | BSA | 11.3d | 9.0 | 32.6% | mRECIST | - | 8 | 10 | 4 |
| Soydal et al20 | 2016 | Resin | BSA | 8.1 | 9.7 | N/A | RECIST | - | - | - | - |
| Swinburne et al19 | 2017 | Resin/glass | BSA; Othera | 8.4d | 9.1 | N/A | RECIST | 0 | 3 | 16 | 7 |
| Reimer et al18 | 2018 | Resin | BSA | N/A | 15.0 | N/A | RECIST | 0 | 1 | 9 | 11 |
| Orwat et al17 | 2017 | Resin/glass | BSA | N/A | 5.2 | N/A | N/A | N/A | N/A | N/A | N/A |
| Paprottka et al16 | 2017 | Resin | mBSA | N/A | 14.3 | N/A | RECIST | N/A | N/A | N/A | N/A |
| Gangi et al13 | 2018 | Glass | Otherb | 9.8 | 12.0 | 49.0% | RECIST | 0 | 5 | 52 | 24 |
| Filippi et al11 | 2015 | Resin | BSA | N/A | 17.0 | N/A | PERCIST | 0 | 14 | 3 | 0 |
| Beuzit et al12 | 2016 | Glass | N/A | N/A | 19.0 | 54.0% | RECIST | 0 | 6 | 32 | 7 |
| Choi | - | 37 | 2 | 6 | |||||||
| Shaker et al14 | 2018 | Resin/glass | N/A | 21.3d | 33.6 | N/A | N/A | N/A | N/A | N/A | N/A |
| Camacho et al15 | 2014 | Resin | BSA; otherc | N/A | 16.3 | N/A | RECIST | 0 | 1 | 13 | 2 |
| mRECIST | 2 | 7 | 5 | 2 | |||||||
| EASL | 2 | 6 | 6 | 2 | |||||||
Notes: aTheraSphere dosimetry was calculated based upon a desired radiation treatment dose for a targeted portion of the liver. bDosimetry was calculated based on the treated liver volume, the administered activity, and the lung shunt fraction. cDosimetry was based on tumor volumetry and then adjusted by the pulmonary shunt fraction. dMean follow-up.
Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors; PERCIST, Positron Emission Tomography Response Criteria in Solid Tumors; mRECIST, modified RECIST; EASL, the European Association for the Study of the Liver; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OS, overall survival; N/A, not available; BSA, body surface area.